Isomorphic Labs Series B轮融资21亿美元：从DeepMind走出的AI制药先锋，获Thrive Capital领投
Isomorphic Labs Series B $21亿 — 当一家公司还在探索AI如何预测蛋白质结构时，另一家公司已经用AI设计出进入临床的候选药物，并拿到了21亿美元的巨额融资。Isomorphic Labs，这家从Google De
在行业技术变革与商业化落地加速推进的背景下，前沿硬科技公司 Isomorphic Labs 正式宣布完成 $21亿 的 Series B 融资。本轮融资由 Thrive Capital (lead), Alphabet, GV, MGX, Temasek, 等知名机构联合重仓投出。随着本轮资本的注入，Isomorphic Labs 正在围绕【从DeepMind走出的AI制药先锋，获Thrive Capital领投】加速构建其核心产品矩阵与商业化交付壁垒。
| 信息维度 | 详情内容 |
|---|---|
| 公司名称 | Isomorphic Labs |
| 融资金额 | $21亿 |
| 融资轮次 | Series B |
| 核心投资方 | Thrive Capital (lead), Alphabet, GV, MGX, Temasek, |
| 核心战略焦点 | 从DeepMind走出的AI制药先锋，获Thrive Capital领投 |
| 官方网站 | https://isomorphiclabs.com |
核心痛点与行业背景：从DeepMind走出的AI制药先锋，获Thrive Capital领投
核心业务与技术细节：Isomorphic Labs, an AI-first drug discovery company spun out of Google DeepMind, has raised $2.1 billion in Series B funding. The round was led by Thrive Capital, with participation from Alphabet, GV, and new investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Founded in 2021 by Demis Hassabis (CEO of Google DeepMind), Isomorphic Labs builds upon DeepMind’s foundational AlphaFold technology to reimagine drug discovery. The company’s AI drug design engine, known as IsoDDE (Isomorphic Drug Design Engine), enables computational design of novel drug candidates. The funding will further develop and deploy IsoDDE, accelerate therapeutic programs toward the clinic, and scale the business globally. Isomorphic Labs has established high-profile partnerships with Eli Lilly, Novartis, and Johnson & Johnson to apply its AI technology to drug development.
产品路线与核心壁垒：从技术研发到商业化交付
Isomorphic Labs 的核心竞争优势在于其自研的技术架构与严谨的工程化落地能力。通过将核心算法与企业现有业务流程无缝打通，公司大幅降低了客户的部署周期与迁移成本，实现了可量化的ROI提升。
资本逻辑与未来展望：Smart Money 重仓的深层原因
本轮领投机构 Thrive Capital (lead), Alphabet, GV, MGX, Temasek, 选择重仓 Isomorphic Labs，核心在于看好团队在硬核技术领域的扎实积累与商业化执行力。本轮融资资金将主要用于产品长线迭代、核心团队扩充以及全球市场商业化网络的深耕。
RecodeX 极客视点：Isomorphic Labs 的融资展现了创投市场对硬核技术与清晰商业化闭环的高度认可。随着技术演进与赛道洗牌加剧，Isomorphic Labs 能否持续保持产品领先性并扩大市场渗透率，将是其未来跃升行业领头羊的关键。
